نتائج البحث

Intermediate PSA half-life after neoadjuvant hormone therapy predicts reduced risk of castration-resistant prostate cancer development after radical prostatectomy

• Authors : Yong Jin Kang; Won Sik Jang; Jong Kyou Kwon

Subjects: Prostate; Neoadjuvant androgen deprivation therapy; Prostate-specific antigen

• Source: BMC Cancer, Vol 17, Iss 1, Pp 1-8 (2017)

تفاصيل العنوان

Intermediate PSA half-life after neoadjuvant hormone therapy predicts reduced risk of castration-resistant prostate cancer development after radical prostatectomy.

• Authors : Kang YJ; Department of Urology, Urological Science Institute, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, Republic of Korea.; Jang WS

Subjects: Biomarkers, Tumor*; Prostate-Specific Antigen/Prostate-Specific Antigen/Prostate-Specific Antigen/*blood ; Prostatic Neoplasms, Castration-Resistant/Prostatic Neoplasms, Castration-Resistant/Prostatic Neoplasms, Castration-Resistant/*blood

• Source: BMC cancer [BMC Cancer] 2017 Nov 23; Vol. 17 (1), pp. 789. Date of Electronic Publication: 2017 Nov 23.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

تفاصيل العنوان

Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety.

• Authors : Bernhard W; Department of Pathology and Laboratory Medicine, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.; Barreto K

Subjects: Drugs, Investigational/Drugs, Investigational/Drugs, Investigational/*administration & dosage ; Immunoconjugates/Immunoconjugates/Immunoconjugates/*administration & dosage ; Neoplasms/Neoplasms/Neoplasms/*diagnostic imaging

• Source: BMC cancer [BMC Cancer] 2021 Mar 12; Vol. 21 (1), pp. 270. Date of Electronic Publication: 2021 Mar 12.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

تفاصيل العنوان

Comparative research on 99m Tc-Rituximab and 99m Tc-sulfur colloid in sentinel lymph node imaging of breast cancer.

• Authors : Zhang JJ; Department of nuclear medicine, Hebei General Hospital, Shijiazhuang, China.; Zhang WC

Subjects: Breast Neoplasms/Breast Neoplasms/Breast Neoplasms/*pathology ; Colloids/Colloids/Colloids/*chemistry ; Organotechnetium Compounds/Organotechnetium Compounds/Organotechnetium Compounds/*administration & dosage

• Source: BMC cancer [BMC Cancer] 2019 Oct 15; Vol. 19 (1), pp. 956. Date of Electronic Publication: 2019 Oct 15.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

تفاصيل العنوان

Biological evaluation of novel gemcitabine analog in patient-derived xenograft models of pancreatic cancer.

• Authors : Inkoom, Andriana¹ (AUTHOR); Ndemazie, Nkafu Bechem¹ (AUTHOR); Smith, Taylor¹ (AUTHOR)

• Source: BMC Cancer. 5/13/2023, Vol. 23 Issue 1, p1-21. 21p.

تفاصيل العنوان

First-in-human study of GFH018, a small molecule inhibitor of transforming growth factor-β receptor I inhibitor, in patients with advanced solid tumors.

• Authors : Guo, Ye¹ (AUTHOR); Wang, Zishu² (AUTHOR); Zhou, Huan² (AUTHOR)

• Source: BMC Cancer. 4/10/2024, Vol. 24 Issue 1, p1-13. 13p.

تفاصيل العنوان

Comparative research on 99mTc-Rituximab and 99mTc-sulfur colloid in sentinel lymph node imaging of breast cancer

• Authors : Xiaomin Li; Jing-Jie Zhang; Cai-Xia An

Subjects: Adult; Cancer Research; Sentinel lymph node

• Source: BMC Cancer, Vol 19, Iss 1, Pp 1-7 (2019)BMC Cancer

تفاصيل العنوان

PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours.

• Authors : McKeage MJ; The University of Auckland, Auckland, New Zealand. ; Jameson MB

Subjects: Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*therapeutic use ; Neoplasms/Neoplasms/Neoplasms/*drug therapy ; Prodrugs/Prodrugs/Prodrugs/*administration & dosage

• Source: BMC cancer [BMC Cancer] 2012 Oct 25; Vol. 12, pp. 496. Date of Electronic Publication: 2012 Oct 25.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

تفاصيل العنوان

The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors.

• Authors : Lee CM; Divisions of Applied Molecular Oncology and Medical Oncology and Hematology Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada.; Tannock IF

Subjects: Antibodies, Monoclonal/Antibodies, Monoclonal/Antibodies, Monoclonal/*pharmacokinetics ; Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*pharmacokinetics ; Breast Neoplasms/Breast Neoplasms/Breast Neoplasms/*metabolism

• Source: BMC cancer [BMC Cancer] 2010 Jun 03; Vol. 10, pp. 255. Date of Electronic Publication: 2010 Jun 03.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

تفاصيل العنوان

A novel PEGylated form of granulocyte colony-stimulating factor, mecapegfilgrastim, for peripheral blood stem cell mobilization in patients with hematologic malignancies.

• Authors : Wen, Jingjing¹ (AUTHOR); Zhou, Qiaolin¹ (AUTHOR); Shi, Lin² (AUTHOR)

• Source: BMC Cancer. 7/24/2023, Vol. 23 Issue 1, p1-8. 8p.

تفاصيل العنوان